CareDx, Inc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CDNA research report →
Range $46 – $100
Price Chart
About the company
CareDx, Inc. is a global innovator specializing in the discovery, development, and commercialization of diagnostic and management tools designed for transplant recipients and their healthcare providers. The company's extensive portfolio features a range of specialized diagnostic solutions for organ monitoring, including: AlloSure Kidney, AlloSure Heart, and AlloSure Lung: Advanced tests employing donor-derived cell-free DNA (dd-cfDNA) technology to assess the health of kidney, heart, and lung transplants, respectively.
- CEO
- John Walter Hanna Jr.
- IPO
- 2014
- Employees
- 763
- HQ
- Brisbane, CA, US
Get TickerSpark's AI analysis on CDNA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $3.68B
- P/E
- 29.63
- Fwd P/E
- 39.36
- PEG
- -0.03
- P/S
- 7.79
- P/B
- 8.23
- EV/EBITDA
- 128.08
- Div Yield
- 0.00%
- Gross Margin
- 70.97%
- Op Margin
- 0.83%
- Net Margin
- 25.86%
- ROE
- 34.08%
- ROIC
- 0.81%
Latest fiscal year · YoY change
- Revenue
- $379.81M+13.8%
- Gross Profit
- $256.57M+14.5%
- Op Income
- $-25,071,000
- Net Income
- $-21,354,000-140.6%
- EPS
- $-0.40-140.0%
- OCF Growth
- +10.5%
- FCF Growth
- +14.4%
- 52W High
- $90.87
- 52W Low
- $15.56
- 50D MA
- $68.21
- 200D MA
- $37.78
- Beta
- 2.49
- RSI (14)
- 46
- Avg Volume
- 1.31M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
CareDx posted a strong Q3 with broad-based testing growth, higher margins, and raised full-year guidance as transplant and NavDx momentum continued.· October 29, 2026
- Revenue rose 39% year over year to $139 million; non-GAAP gross margin improved to 74% from 71%.
- Testing volume increased 51% year over year to 75,900 tests, with transplant volume up 21% and specialty oncology volume at 15,150 tests.
- Adjusted EBITDA doubled to $30 million, or 22% of revenue, and the company ended with $250 million in cash and no debt.
- Full-year 2026 guidance was raised to $520 million-$530 million in revenue and $90 million-$100 million in adjusted EBITDA.
- Management said transplant demand remained strong, NavDx integration is progressing, and both AlloHeme and HistoMap Kidney remain on track for 2027 launches.
For Q3 2026, CareDx reported revenue of $139 million, up 39% year over year, and testing volume of 75,900 tests, up 51% year over year. Non-GAAP gross margin was 74%, versus 71% in the prior-year quarter, and adjusted EBITDA was $30 million, or 22% of revenue, up from $15 million a year ago. Cash and cash equivalents were $250 million at quarter-end, with no debt. Excluding out-of-period revenue, total revenue grew 32% year over year and 7% sequentially. Testing services revenue was $119 million, up 65% year over year, and transplant revenue alone increased 39% year over year and 9% sequentially excluding out-of-period revenue. Specialty oncology revenue was $12.5 million. For full-year 2026, management raised revenue guidance to $520 million-$530 million and adjusted EBITDA guidance to $90 million-$100 million. For Q4 2026, they guided to revenue of $131 million-$141 million, testing services revenue of $112 million-$122 million, non-GAAP gross margin of 71%-72%, and adjusted EBITDA of $16 million-$26 million.
John Hanna framed the quarter as one of strong execution across the company’s core transplant business, specialty oncology, and pipeline. He emphasized CareDx’s strategy of building evidence, integrating into clinician workflows, and making testing easier to adopt across transplantation, oncology, and future cell therapy markets. His tone was confident and upbeat, especially around pipeline progress, saying AlloHeme and HistoMap Kidney remain on track for 2027 and that NavDx integration and transplant protocol adoption are expanding.
Keith Kennedy highlighted strong top-line growth, margin expansion, and cash generation. He cited Q3 revenue of $139 million, gross margin of 74%, adjusted EBITDA of $30 million, and $13 million in operating cash flow, while noting $11 million of seller-funded transaction expenses and $1.5 million of option-related compensation tied to the NavDx deal. He also said the company ended the quarter with $250 million in cash and no debt, and raised full-year guidance to $520 million-$530 million in revenue and $90 million-$100 million in adjusted EBITDA. He added that NavDx revenue per test was $823 in the quarter and that he sees a path to $1,000 or higher over time, while transplant ASPs are still working toward a $2,000 per test target.
Analysts focused on whether the August LCD changed physician behavior; John Hanna said it had not impacted utilization and instead removed an overhang, with growth continuing quarter over quarter. Questions also centered on NavDx pricing, transplant ASP upside, and the durability of out-of-period revenue; Keith Kennedy said NavDx pricing can rise over time and reiterated a long-term target of around 2% of revenue from out-of-period items. Management also addressed transplant mix and runway, saying kidney, lung, and heart are all growing, with lung showing especially strong growth due to deeper testing and digital support, and that for-cause and surveillance use cases both remain important. On AlloHeme, management said publication of ACROBAT, CLIA readiness, and coverage submission are the key milestones, with coverage potentially in 2028 and meaningful revenue in 2029.
The bull case is that CareDx is showing durable growth in its core transplant franchise while integrating NavDx faster than expected and improving profitability at the same time. Management also pointed to multiple evidence-generation catalysts and a pipeline that could broaden the company’s addressable market in 2027, with strong workflow integration and patient engagement tools supporting adoption.
The main risks are that a meaningful portion of near-term growth still depends on continued protocol adoption, payer/reimbursement execution, and successful integration of recent acquisitions. The company also flagged that some revenue depends on out-of-period collections, and newer programs like AlloHeme and HistoMap still need CLIA readiness, publication, and coverage before they can become major contributors.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 96.7%
- Shares Outstanding
- 52.54M
- Float Shares
- 50.80M
of shares held by institutions
233 13F filers
Buy/sell ratio 0.15. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for CDNA, newest first.
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 4.87M | ▲ 57.08K |
| Vanguard Group Inc | 3.43M | ▼ 321.45K |
| State Street Corp | 2.62M | ▲ 154.21K |
| Vanguard Capital Management LLC | 2.19M | ▼ 3.92K |
| Arrowstreet Capital, Limited Partnership | 2.06M | ▲ 1.69M |
| Deerfield Management Company, L.P. | 2.00M | ▼ 193.38K |
| Bamco Inc | 1.94M | ▼ 1.40M |
| Blue Water Life Science Advisors, LP | 1.74M | ▲ 550.00K |
| Ark Investment Management LLC | 1.61M | ▼ 344.48K |
| Geode Capital Management, LLC | 1.48M | ▲ 152.56K |
| Chevy Chase Trust Holdings, LLC | 1.35M | ▼ 84.63K |
| Ophir Asset Management Pty Ltd | 1.26M | ▲ 276.76K |
Held by 319 ETFs
Biggest fund positions in CDNA by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 16, 26 | Riggsbee Richard Bryan | sell | 2,418 |
| Nov 16, 26 | Riggsbee Richard Bryan | sell | 1,667 |
| Nov 16, 26 | Riggsbee Richard Bryan | sell | 800 |
| Nov 16, 26 | Riggsbee Richard Bryan | sell | 400 |
| Nov 12, 26 | Goldberg Michael | sell | 3,547 |
| Nov 12, 26 | Goldberg Michael | sell | 8,024 |
| Nov 12, 26 | Goldberg Michael | sell | 2,229 |
| Nov 12, 26 | Kennedy Keith | other | 2,097 |
| Nov 12, 26 | Kennedy Keith | sell | 800 |
| Nov 12, 26 | Kennedy Keith | sell | 1,297 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CDNA coverage
Recent articles, reports, and earnings notes.
Want a deeper read on CDNA?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
CareDx to Participate in Upcoming Investor Conferences
businesswire.com · Nov 20
CytomX Therapeutics (NASDAQ:CTMX) and CareDx (NASDAQ:CDNA) Critical Analysis
defenseworld.net · Nov 19
Wall Street Analysts Think CareDx (CDNA) Could Surge 28.09%: Read This Before Placing a Bet
zacks.com · Nov 17
CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com · Nov 6
CareDx (CDNA) Upgraded to Strong Buy: Here's What You Should Know
zacks.com · Nov 6
Polen 5Perspectives Ultra-Small Growth Q3 2026 Portfolio Review
seekingalpha.com · Nov 4
Baron Discovery Fund Q3 2026 Portfolio Activity
seekingalpha.com · Nov 4
CareDx Q3 Earnings Call Highlights Raised '26 Outlook & Testing Growth
zacks.com · Nov 3
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
